Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPOX | P50336 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9873170 | 0.86 | NPC1 (0.37) | PPOXMAPTALDH1A1KDM4EHSD17B10 | |
| SCHEMBL8604315 | 0.86 | CSNK2A1 (0.49) | PPOXMAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL27304096 | 0.85 | NPC1 (0.46) | PPOXMAPTALDH1A1KDM4EHSD17B10 | |
| SCHEMBL8599263 | 0.84 | GLA (0.50) | PPOXMAPTALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL19088271 | 0.84 | PPOX (0.46) | PPOXMAPTALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL11436726 | 0.84 | MAPT (0.48) | PPOXMAPTALDH1A1KDM4EHSD17B10 | |
| SCHEMBL9684646 | 0.84 | L3MBTL1 (0.39) | PPOXMAPTALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL8602962 | 0.83 | SMN1; SMN2 (0.46) | PPOXMEN1HPGDKMT2ANPC1 | |
| SCHEMBL19088273 | 0.82 | PPOX (0.45) | PPOXMAPTALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL17543319 | 0.82 | MAPT (0.47) | MAPTALDH1A1KDM4EHSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106795117-B | Heterobicyclic compounds and their use for the treatment of tuberculosis | 大塚制药株式会社 | 2020-06-26 | — | — | CN | disclosed |
| US-10464926-B2 | Heterobicyclic compounds and their use for the treatment of tuberculosis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-11-05 | — | — | US | disclosed |
| EP-3186240-B1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2019-06-12 | — | — | EP | disclosed |
| US-20180312488-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-11-01 | — | — | US | disclosed |
| US-10053446-B2 | Heterobicyclic compounds and their use for the treatment of tuberculosis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-08-21 | — | — | US | disclosed |
| US-20170253576-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-09-07 | — | — | US | disclosed |
| EP-3186240-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016031255-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-03-03 | — | — | WO | disclosed |
| EP-0626370-B1 | Process for producing aromatic isothiocyanate derivatives | SUMITOMO CHEMICAL CO (JP) | 1998-02-11 | — | — | EP | disclosed |
| CN-1036564-C | Herbicidal glutarmides | ROHM & HAAS (US) | 1997-12-03 | — | — | CN | disclosed |
| US-5502027-A | ALGICIDES | ROHM AND HAAS COMPANY (US) | 1996-03-26 | — | — | US | disclosed |
| EP-0415642-B1 | Glutarimides | ROHM & HAAS (US) | 1995-12-06 | — | — | EP | disclosed |
| US-5393735-A | N-(halo-oxy-)phenyl substituted cyclic imides | ROHM AND HAAS COMPANY (US) | 1995-02-28 | — | — | US | disclosed |
| EP-0626370-A1 | Process for producing aromatic isothiocyanate derivatives | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1994-11-30 | — | — | EP | disclosed |
| EP-0415641-B1 | Substituted glutaramic acids and derivatives | ROHM & HAAS (US) | 1994-01-19 | — | — | EP | disclosed |
| US-5238908-A | HERBICIDAL GLUTARAMIC ACIDS AND DERIVATIVES | ROHM AND HAAS COMPANY (US) | 1993-08-24 | — | — | US | disclosed |
| CN-1049770-A | Weeding glutaramic acid and its derivative | ROHM & HAAS (US) | 1991-03-13 | — | — | CN | disclosed |
| CN-1049846-A | Glutarimide with weeding activity | ROHM & HAAS (US) | 1991-03-13 | — | — | CN | disclosed |
| EP-0415641-A1 | Substituted glutaramic acids and derivatives | ROHM AND HAAS COMPANY (US) | 1991-03-06 | — | — | EP | disclosed |
| EP-0415642-A1 | Glutarimides | ROHM AND HAAS COMPANY (US) | 1991-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053446-B2 | Heterobicyclic compounds and their use for the treatment of tuberculosis | FNTB, SLC11A2, TBCD | PPOX 3110/4885MAPT 1813/4885ALDH1A1 1458/4885 |
| US-10464926-B2 | Heterobicyclic compounds and their use for the treatment of tuberculosis | FNTB, SLC11A2, TBCD | PPOX 3110/4885MAPT 1813/4885ALDH1A1 1458/4885 |
| US-20180312488-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | FNTB, SLC11A2, TBCD | PPOX 3110/4885MAPT 1813/4885ALDH1A1 1458/4885 |
| US-20170253576-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | FNTB, SLC11A2, TBCD | PPOX 3110/4885MAPT 1813/4885ALDH1A1 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.